Literature DB >> 16313114

[Effect of tongxinluo on endothelin-1 in the mini-swine model of acute myocardial infarction and reperfusion].

Jing-lin Zhao1, Yue-jin Yang, Shi-jie You, Zhicheng Jin, Yongjian Wu, Weixian Yang, Jilin Chen, Runlin Gao, Zaijia Chen.   

Abstract

OBJECTIVE: To evaluate the change of endothelin-1 (ET-1) in the mini-swine model of acute myocardial infarction (AMI) and reperfusion and the effect of Tongxinluo (TXL) on it, and to explore the possible mechanism of no-reflow.
METHODS: Forty mini-swines were randomized into 5 groups: the model group, the small,middle and large dose of TXL groups and the sham-operated group, 8 in each group. The AMI reperfusion model was established by coronary ligation for 3 hrs followed with relaxation for 1 hr. Plasma ET-1 content before and after AMI, and after reperfusion was determined respectively by radioimmunoassay. The ET-1 mRNA expression in myocardial tissue of normal, ischemic and no-reflow area were respectively quantified by reverse transcription-polymerase chain reaction.
RESULTS: (1) Compared with before AMI, levels of plasma ET-1 at the time points of 5 min and 3 hrs after AMI, 5 min and 1 hrs after reperfusion in the model group were significantly raised, showing an increasing tendency (all P < 0.01). But the increment in the middle and large dose of TXL groups were all lower than that in the model group (P < 0.05). (2) In the model and the TXL groups, levels of ET-1 in myocardial tissue of ischemic and no-reflow area were significantly higher than those in the normal area, and the increment in no-reflow area was higher than that in ischemic area (all P < 0.01). Compared with the model group, significant lowering of ET-1 in ischemic area was only shown in the middle and large dose of TXL groups (P < 0.01). (3) In the model and the TXL groups, ET-1 mRNA expression in ischemic area was significantly higher (all P < 0.01), while it in no-reflow area was significantly lower than that in the normal area respectively (all P < 0.01). The raised ET-1 mRNA expression in the middle and large dose TXL groups was significantly lowered when compared with that in the model group (P < 0.01).
CONCLUSION: The endothelium injury might be one of the important mechanisms for no-reflow phenomenon. TXL might reduce the no-reflow by protecting endothelium cells. was significantly higher (all P < 0.01), while it in no-reflow area was significantly lower than that in the normal area respectively (all P < 0.01). The raised ET-1 mRNA expression in the middle and large dose TXL groups was significantly lowered when compared with that in the model group (P < 0.01). Conclusion The endothelium injury might be one of the important mechanisms for no-reflow phenomenon. TXL might reduce the no-reflow by protecting endothelium cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16313114

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  3 in total

Review 1.  Tongxinluo Capsule () for Cardiac Syndrome X: A Systematic Review and Meta-Analysis.

Authors:  Hui-Min Mao; Mi Liu; Hua Qu; Li-Qiong Wang; Da-Zhuo Shi
Journal:  Chin J Integr Med       Date:  2017-08-17       Impact factor: 1.978

2.  Effects of tongxinluo on the neointima formation and expression of inflammatory cytokines in rats after carotid artery balloon injury.

Authors:  En-Hui Yao; Hua-Jun Wang; Chang-Sheng Xu
Journal:  Indian J Pharmacol       Date:  2014 Sep-Oct       Impact factor: 1.200

3.  China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial.

Authors:  Yi Xu; Xiangdong Li; Haitao Zhang; Yuan Wu; Jun Zhang; Jia Li; Kefei Dou; Hongbing Yan; Shijie You; Yanmin Yang; Yan Liang; Lianjun Xu; Xiaojin Gao; Chen Liu; Qiuting Dong; Wenjia Zhang; Guangyuan Song; Tao Zhang; Lin Jiang; Guihao Chen; Ruijie Tang; Chen Jin; Jingang Yang; Chen Yao; Ying Xian; Eric D Peterson; Runlin Gao; Yuejin Yang
Journal:  Am Heart J       Date:  2020-06-20       Impact factor: 4.749

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.